Results 201 to 210 of about 85,863 (235)

CAR‐T Cell Therapy in Autoimmune Setting: A New Appealing Approach Extendable to Allergy?

Allergy, EarlyView.
Federico Rossi, Rubén Fernandez Santamaria, Riccardo Castagnoli   +2 more
wiley   +1 more source

Natural products targeting tumour angiogenesis

British Journal of Pharmacology, Volume 182, Issue 10, Page 2094-2136, May 2025.
Abstract Tumour angiogenesis is the formation of new blood vessels to support the growth of a tumour. This process is critical for tumour progression and metastasis, making it an attractive approach to cancer therapy. Natural products derived from plants, animals or microorganisms exert anti‐angiogenic properties and can be used to inhibit tumour ...
Xiaohua Lu, Lara Johanna Friedrich, Thomas Efferth   +2 more
wiley   +1 more source

Role of Renal Resistive Index as an Early Marker of Diabetic Nephropathy in Children With Type 1 Diabetes Mellitus. [PDF]

Cureus
Choudhary P, Rani M, Sengar GS.
europepmc   +1 more source

GNS561 (ezurpimtrostat), a small basic lipophilic molecule, prevents lupus phenotype in a pristane‐induced lupus mouse model

British Journal of Pharmacology, EarlyView.
Background and Purpose Systemic lupus erythematosus is an autoimmune, multisystemic disease affecting all organs in the body. Accrued evidence has elucidated a role for autophagy in the onset and severity of systemic lupus erythematosus. The antimalarial drug hydroxychloroquine constitutes the cornerstone of standard of care for systemic lupus ...
Eya Toumi, Eloïne Bestion, Muriel Militello, Hubert Lepidi, Anne Plauzolles, Nathalie Bardin, Daniel Bertin, Laurent Chiche, Jean‐Louis Mege, Philippe Halfon, Soraya Mezouar   +10 more
wiley   +1 more source

Prevalence of nephropathy among patients with diabetes mellitus in Africa: a systematic review and meta-analysis. [PDF]

Front Clin Diabetes Healthc
Adebayo-Gege GI, Adegbola PI, Adedayo LD, Oyefabi AM, Oyeyemi IT, Olubukola O, Oke AA, Okeke OP, Abodunrin OR, Akinsolu FT, Sobande OO.   +10 more
europepmc   +1 more source

Advancing antihypertensive drug development

British Journal of Pharmacology, EarlyView.
Hypertension affects more than a billion individuals worldwide and remains a major cause of cardiovascular morbidity and mortality. Despite advances in therapies, optimal blood pressure control remains elusive for many patients because of treatment resistance, adverse effects, and adherence challenges.
Fay Pu, Yanrong Liu, Fozia Zahir Ahmed, Xin Wang, Darren Green, Hongyuan Zhang   +5 more
wiley   +1 more source

Urinary Dickkopf-related protein 3 as a novel biomarker for kidney function decline in children with Alport syndrome. [PDF]

Pediatr Nephrol
Boeckhaus J, Tönshoff B, Weber LT, Pape L, Latta K, Fehrenbach H, Lange-Sperandio B, Kettwig M, König S, John-Kroegel U, Gellermann J, Galiano M, Jami S, Pieper D, Dihazi GH, Hafke A, Kohl S, Liebau MC, König J, Haffner D, Gross O, Wallbach M.   +21 more
europepmc   +1 more source

Effect of glucagon‐like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta‐analysis

Clinical Obesity, EarlyView.
Summary The effect of glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) on systolic blood pressure (SBP) in patients with obesity with or without diabetes remains unclear. The aim was to compare the effect of different drug–dose combinations of GLP‐1RAs on SBP.
Abraish Ali, Asad Ali Siddiqui, Muhammad Shariq Usman, Izza Shahid, Muhammad Shahzeb Khan, Prinka Perswani   +5 more
wiley   +1 more source

SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application. [PDF]

Diabetes Metab J
Bae JH.
europepmc   +1 more source